First PMTA success for Reynolds’s Vuse products – but tobacco flavours only

The US Food and Drug Administration (FDA) has issued its first marketing authorisations for e-cigarette products, following the rejection of millions of others.

The authorisations cover RJ Reynolds’s Vuse Solo device and two 4.8% nicotine tobacco-flavoured pods, which the FDA said exposed users to reduced risk compared to combustible cigarettes. While the authorisations allow the products to be sold legally in the US, the FDA did impose limits on digital, TV and radio advertising.

...

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Restricted content. Do you want to read more?

Request report

Interested in buying?
Request more information

MORE INFO

Visit store

Check out our reports
available for purchase

View reports

Request a free sample of this report:

“ First PMTA success for Reynolds’s Vuse products – but tobacco flavours only ”

    This file is not available, please fill the form to request your sample page:






    Buy report request information:

    “ First PMTA success for Reynolds’s Vuse products – but tobacco flavours only ”






      The US Food and Drug Administration (FDA) has issued its first marketing authorisations for e-cigarette products, following the rejection of millions of others.

      The authorisations cover RJ Reynolds’s Vuse Solo device and two 4.8% nicotine tobacco-flavoured pods, which the FDA said exposed users to reduced risk compared to combustible cigarettes. While the authorisations allow the products to be sold legally in the US, the FDA did impose limits on digital, TV and radio advertising.

      ...

      Benefits of subscription plans:

      • Stay informed of any legal and market change in the sector that impacts your organization
      • Maximise resources by getting market and legal data analysis daily in one place
      • Make smart decisions by understanding how the regulatory and market landscape evolves
      • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

      Need help?

      Contact a sales representative right now and don’t wait

      Erik Galavis
      +34 654 320 547
      Email Erik